Stemline Therapeutics, Inc. (STML)
| Market Cap | 621.20M |
| Revenue (ttm) | 47.04M |
| Net Income (ttm) | -70.70M |
| Shares Out | 52.50M |
| EPS (ttm) | -1.58 |
| PE Ratio | n/a |
| Forward PE | 17.92 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Jun 10, 2020 |
| Last Price | $11.83 |
| Previous Close | $11.83 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 11.82 - 12.10 |
| Day's Volume | 0 |
| 52-Week Range | 3.21 - 18.22 |
News
Stemline Therapeutics (STML) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here's what's behind their impressive market performances.
The ultimate binary event caused the biotech's shares to jump.
The New York-based oncology-focused, commercial-stage biopharma Stemline Therapeutics Inc (NASDAQ: STML) ringed in merger Monday with a go-private deal valued at up to $667 million.
Privately held Menarini Group, an Italian drug and diagnostics company, said Monday it has agreed to acquire Stemline Therapeutics Inc.
FLORENCE, Italy and NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics Inc., a commercial-s...
Stemline Therapeutics (STML) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sell-side analysts on Wall Street recommend to buy shares of Stemline Therapeutics Inc (NASDAQ:STML) and KalVista Pharmaceuticals Inc (NASDAQ:KALV), even though their share prices have lost mo...
Sell-side analysts on Wall Street recommend to buy shares of Stemline Therapeutics Inc (NASDAQ:STML) and KalVista Pharmaceuticals Inc (NASDAQ:KALV), even though their share prices have lost mo...
Stemline Therapeutics, Inc. (STML) CEO Ivan Bergstein on Q4 2019 Results - Earnings Call Transcript
Stemline Therapeutics (STML) delivered earnings and revenue surprises of 2.56% and 0.08%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for th...
Shares have lost a third of their value since my August recommendation.
NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics, Inc. (STML) CEO Ivan Bergstein on Q3 2019 Results - Earnings Call Transcript
NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress
NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of nove...
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of nove...
The stock of Stemline Therapeutics has fallen approximately 30% from recent highs over the past month.
NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of nove...
NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of nove...
CEO of Stemline Therapeutics Inc (30-Year Financial, Insider Trades) Ivan Bergstein (insider trades) sold 35,010 shares of STML on 08/14/2019 at an average price of $14.73 a share.
Stemline Therapeutics, Inc. (STML) CEO Ivan Bergstein on Q2 2019 Results - Earnings Call Transcript
Stemline Therapeutics (STML) delivered earnings and revenue surprises of 10.64% and 47.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the ...
Today, we revisit Stemline Therapeutics, a developmental concern advancing its pipeline and rolling out its first approved product.
Stemline Therapeutics Inc. reported a wider first-quarter net loss per share Friday, dragged by higher R&D expenses, which nearly tripled from a year ago.
Stemline Therapeutics' (STML) CEO Ivan Bergstein on Q1 2019 Results - Earnings Call Transcript
Stemline Therapeutics (STML) delivered earnings and revenue surprises of -8.96% and 93.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the...
Today we revisit Stemline Therapeutics, a member of the 20-stock Busted IPO Forum model portfolio.
About STML
Stemline Therapeutics, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and Europe. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis... [Read more...]
| Industry Biotechnology | IPO Date Jan 29, 2013 |
| CEO Ivan Bergstein | Employees 100 |
| Stock Exchange NASDAQ | Ticker Symbol STML |
Financial Performance
In 2019, STML's revenue was $43.22 million, an increase of 8,543.37% compared to the previous year's $500,000. Losses were -$76.82 million, -9.65% less than in 2018.